7 Hills Pharma, Inc.
7 Hills Pharma is a clinical-stage drug development company dedicated to advancing first-in-class integrin-targeted agonists designed to safely improve the effectiveness of immunotherapies for cancer and stem cell transplantation. The company aims to build a world where safe and effective cancer treatments are accessible to all, emphasizing innovation, compassion, and integrity. It has received over $34 million in grants from NIH institutions and CPRIT, supporting its pioneering research and development efforts.
Industries
Nr. of Employees
small (1-50)
Products
Clinical‑stage oral small‑molecule integrin agonist (investigational)
Orally administered small‑molecule integrin agonist developed to activate lymphocyte integrin pathways to enhance T cell activation and tumor trafficking; evaluated in combination with immune checkpoint inhibitors in early‑phase oncology trials.
IND‑enabling small‑molecule integrin activator for stem‑cell engraftment
Small‑molecule integrin activator in preclinical and IND‑enabling development aimed at improving hematopoietic stem cell engraftment and reducing post‑transplant infection risk when used as an adjunct to stem cell transplantation or cell‑based therapies.
Clinical‑stage oral small‑molecule integrin agonist (investigational)
Orally administered small‑molecule integrin agonist developed to activate lymphocyte integrin pathways to enhance T cell activation and tumor trafficking; evaluated in combination with immune checkpoint inhibitors in early‑phase oncology trials.
IND‑enabling small‑molecule integrin activator for stem‑cell engraftment
Small‑molecule integrin activator in preclinical and IND‑enabling development aimed at improving hematopoietic stem cell engraftment and reducing post‑transplant infection risk when used as an adjunct to stem cell transplantation or cell‑based therapies.
Expertise Areas
- Integrin‑targeted therapeutics
- Early‑phase oncology clinical development
- Vaccine adjuvant and immunostimulant development
- Preclinical immunology and translational research
Key Technologies
- Small‑molecule integrin activators
- Oral small‑molecule formulation
- Preclinical animal disease models (vaccine and tumor models)
- Gene‑expression and translational biomarker profiling